1. Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.
- Author
-
Moodie, Zoe, Dintwe, One, Sawant, Sheetal, Grove, Doug, Huang, Yunda, Janes, Holly, Heptinstall, Jack, Omar, Faatima Laher, Cohen, Kristen, Rosa, Stephen C De, Zhang, Lu, Yates, Nicole L, Sarzotti-Kelsoe, Marcella, Seaton, Kelly E, Laher, Fatima, Bekker, Linda Gail, Malahleha, Mookho, Innes, Craig, Kassim, Sheetal, and Naicker, Nivashnee
- Subjects
- *
HIV prevention , *VIRAL antigens , *IMMUNOGLOBULINS , *CLINICAL trials , *AIDS vaccines , *HIV seroconversion , *RESEARCH funding , *VIRAL antibodies , *HIV - Abstract
Background: The ALVAC/gp120 + MF59 vaccines in the HIV Vaccine Trials Network (HVTN) 702 efficacy trial did not prevent human immunodeficiency virus-1 (HIV-1) acquisition. Vaccine-matched immunological endpoints that were correlates of HIV-1 acquisition risk in RV144 were measured in HVTN 702 and evaluated as correlates of HIV-1 acquisition.Methods: Among 1893 HVTN 702 female vaccinees, 60 HIV-1-seropositive cases and 60 matched seronegative noncases were sampled. HIV-specific CD4+ T-cell and binding antibody responses were measured 2 weeks after fourth and fifth immunizations. Cox proportional hazards models assessed prespecified responses as predictors of HIV-1 acquisition.Results: The HVTN 702 Env-specific CD4+ T-cell response rate was significantly higher than in RV144 (63% vs 40%, P = .03) with significantly lower IgG binding antibody response rate and magnitude to 1086.C V1V2 (67% vs 100%, P < .001; Pmag < .001). Although no significant univariate associations were observed between any T-cell or binding antibody response and HIV-1 acquisition, significant interactions were observed (multiplicity-adjusted P ≤.03). Among vaccinees with high IgG A244 V1V2 binding antibody responses, vaccine-matched CD4+ T-cell endpoints associated with decreased HIV-1 acquisition (estimated hazard ratios = 0.40-0.49 per 1-SD increase in CD4+ T-cell endpoint).Conclusions: HVTN 702 and RV144 had distinct immunogenicity profiles. However, both identified significant correlations (univariate or interaction) for IgG V1V2 and polyfunctional CD4+ T cells with HIV-1 acquisition. Clinical Trials Registration . NCT02968849. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF